Lentivirus News and Research

RSS

Lentivirus is a genus of slow viruses of the Retroviridae family, characterized by a long incubation period.

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization.

28 Dec 2021

Importance of booster vaccine doses for maintaining protection against the SARS-CoV-2 Omicron variant

A new study shows that although the Omicron variant exhibits significant immune escape compared to other SARS-CoV-2 variants, antibody neutralization can be largely restored with booster doses of mRNA vaccines.

22 Dec 2021

Omicron evades immunity more than other SARS-CoV-2 variants

Researchers find that the SARS-CoV-2 Omicron variant shows a much more extensive escape from vaccine-elicited immunity.

14 Dec 2021

Iota-carrageenan inhibits replication of SARS-CoV-2 VOCs

Scientists have recently reported the efficacy of carrageenan against both the SARS-CoV-2 original strain as well as the Alpha, Beta, Gamma, and Delta VOCs.

13 Dec 2021

Custom Biofluid & Tissue Procurement Service

Global provider of human and animal biospecimens - AMSBIO offers a custom procurement service enabling researchers to source specific biofluid and tissue samples which are not already available in their extensive biorepository.

From AMS Biotechnology 1 Dec 2021

Immunogenicity of modified microparticle-adjuvanted SARS-CoV-2 vaccine

Researchers investigated the immunogenicity of a novel adjuvant comprised of a modified porous silicon microparticle for the SARS-CoV-2 S protein RBD subunit vaccine.

29 Nov 2021

Broad neutralization capability of potent nanobody against SARS-CoV-2 variants

A new study has described the molecular basis of the neutralization potency and breadth of nanobodies.

16 Nov 2021

Novel tetravalent antibodies for the ultrapotent and broad neutralization of SARS-CoV-2 variants

Researchers from the University of Toronto set out to create a new tetravalent antibody that could bind with enough potency that it could remain effective against VOCs.

9 Nov 2021

Convalescent plasma post-vaccination increases binding and neutralizing antibodies against SARS-CoV-2 variants

A recent study assesses the boost in antibodies against SARS-CoV-2)variants post-vaccination in plasma samples from previously infected COVID-19 patients.

7 Nov 2021

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

Increased transmission in open spike conformations of SARS-CoV-2 variants

Researchers from Yale University and the University of Texas have collaborated to investigate mutations in some VOCs.

14 Oct 2021

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

It is demonstrated that palmitoylation of the first five cysteine residues of the C-terminal domain of the SARS-CoV-2 spike protein facilitates cell entry and the formation of syncytia.

11 Oct 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A new study discusses the development of dedicated reagents against the SARS-CoV-2 spike protein through the use of an automated CLEIA system.

28 Sep 2021

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

New research discusses the development of soluble prefusion-stabilized spike trimers (CoV2 preS dTM) comprising adjuvant AS03.

27 Sep 2021

Nanoparticles-assisted delivery of antiviral-siRNA for treatment of COVID-19

A review aimed to determine the potential of siRNA as a potential COVID-19 treatment by reviewing the currently available literature.

10 Sep 2021

Scientists assess SARS-CoV-2 mutants in ferret hosts

In a paper recently uploaded to the preprint server bioRxiv* by the cause of SARS-CoV-2 mutations observed in mink and ferrets is investigated, and the danger posed by such mutations to humans assessed.

26 Aug 2021

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

The safety, immunogenicity, and efficacy of the vaccines in adolescents are largely unknown. Now, a new study published in the New England Journal of Medicine evaluates the safety and efficacy of the mRNA-1273 vaccine in adolescents (12-17 years of age).

16 Aug 2021

New approach could be a useful tool in the fight against cancer drug resistance

Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.

10 Aug 2021